Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
89 hedge funds and large institutions have $271M invested in Chinook Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 14 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 21
49% more call options, than puts
Call options by funds: $305K | Put options by funds: $205K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 92 → 89 (-3)
20% less capital invested
Capital invested by funds: $338M → $271M (-$67.6M)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$8.85M |
| 3 |
BlackRock
New York
|
+$8.84M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.69M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.8M |
| 2 |
Millennium Management
New York
|
-$9.52M |
| 3 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$6.39M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$4.65M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$3.92M |
KDNY Hedge Fund Activity: Q2 2018 in Review
89 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2018, worth a combined $271M — down 20% from $338M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KDNY and 11 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 40 added.
The largest buyer was Citadel Advisors, adding an estimated $11M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $15.8M sold.
- 89 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2018, down from 92 in Q1 2018.
- Funds reported $271M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2018, down 20% quarter-over-quarter.
- 11 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2018 and 14 closed out, a net change of -3 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2018 was Citadel Advisors, an estimated $11M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2018 was Point72 Asset Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q2 2018.